Loss of heterozygosity and DNA methylation affect germline fibroblast growth factor receptor 4 polymorphism to direct allelic selection in breast cancer.
Zhu
Xuegong
X
Department of Medicine, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Zheng
Lei
L
Asa
Sylvia L
SL
Ezzat
Shereen
S
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000483:Alleles; D000818:Animals; D001374:Azacitidine / Q000031:analogs & derivatives / Q000494:pharmacology; D001943:Breast Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D045744:Cell Line, Tumor; D019175:DNA Methylation / Q000187:drug effects / Q000235:genetics; D000077209:Decitabine; D005260:Female; D018095:Germ-Line Mutation / Q000502:physiology; D006801:Humans; D019656:Loss of Heterozygosity / Q000235:genetics; D051379:Mice; D016513:Mice, SCID; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide / Q000502:physiology; D051499:Receptor, Fibroblast Growth Factor, Type 4 / Q000235:genetics* / Q000378:metabolism; D012641:Selection, Genetic / Q000235:genetics / Q000502:physiology; D023041:Xenograft Model Antitumor Assays
D000077209:Decitabine; C496371:FGFR4 protein, human; D051499:Receptor, Fibroblast Growth Factor, Type 4; D001374:Azacitidine